TABLE 1.
Main characteristics of nine HIV-HBV-coinfected patients receiving lamivudine therapy and experiencing HBV relapse
| Parameter | Beginning of lamivudine therapy | Breakthrough |
|---|---|---|
| Median ALT level in serum (times above normal) | 2.6 (1–3)a | 1.8 (1.3–2) |
| Median no. of CD4 lymphocytes/μl | 90 (27–318) | 246 (218–469) |
| HIV type 1 load | ||
| No. of RNA copies/ml of plasmab | 61,674 (393–213,427) | 3,909 (1,851–7,299) |
| No. of patients with no detectable viral load | 2 | 3 |
| No. of untested patients | 2 | 1 |
| HBV load (pg of HBV DNA/ml)c | >2,000 (1,450–>2,000) | 680 (150–1,701) |
| HBV serological markers (no. of subjects positive) | ||
| HBsAg | 9 | 9 |
| HBsAb | 0 | 0 |
| HbeAg | 8 | 9 |
| HbeAb | 1 | 0 |
a
The values in parentheses are 95% confidence intervals, when applicable.
b
Measured by Monitor (Roche). Range of detection, 200 to 1,500,000 copies/ml.
c
Measured by Hybrid Capture (Murex). Range of detection, 2.5 to 2,000 pg/ml.